Menu
Close
Global
×

Company News

Home Company News News detail
ImmuneOnco Biopharmaceuticals' IMM2520 project completes first subject dosing
2023-03-23
1247
Previous article：ImmuneOnco Biopharmaceuticals IMM47, IMM2520 and IMM2510 invention patents were granted by the State Intellectual Property Office of China
Next article：ImmuneOnco Biopharmaceuticals' IMM47, IMM40H, IMM2520, and IMM2902 projects debut at the 2023 American Association for Cancer Research (AACR) Annual Meeting
Back
Hot recommendation
2026-03-30
ImmuneOnco Initiates Phase III Trial of Amouravfop Alfa (IMM0306) in Relapsed/Refractory Follicular Lymphoma
More
2026-03-23
ImmuneOnco Announces Phase III Study of timdarpacept (IMM01) in CMML Reaches Interim Analysis Milestone with 133 Subjects Enrolled
More
2026-03-17
ImmuneOnco Receives NMPA Approval for Phase II Trial of Amouravfop Alfa (IMM0306) in Primary Membranous Nephropathy
More

For more information

Please follow the official wechat public account